Lymphoedema Evidence Library › Topics › Adjuncts: HBOT, laser and others
Adjuncts: HBOT, laser and others
Adjuncts: HBOT, laser, carboxytherapy, negative pressure
97 sources
Evidence in one minute
- No adjunct has shown a clinically important added benefit. Most trials are small, unblinded or manufacturer-run.
- Hyperbaric oxygen: no benefit for chronic arm lymphoedema after breast radiotherapy. A randomised phase II trial (58 patients, 30 sessions at 2.4 ATA) found no volume or function difference at 12 months — low certainty (revised 2026-10-08 from moderate: open label, 79% analysed). Do not motivate HBOT for limb lymphoedema. Gothard 2010
- Low-level laser: a modest size reduction (about 92 mL) against weak comparators and no added effect within decongestive therapy — low. Mahmood 2022 · Yoon 2026
- Taping: no volume reduction — low; inferior to CDT in stage II. Marotta 2023 · Basoglu 2021
- Drugs, supplements and cell therapy: nothing is supported; benzopyrones, selenium and diuretics are not recommended. Walker 2022 · Lommer 2026
- Acupuncture, moxibustion, tuina, electrotherapy and shock wave: small, poorly reported trials — very low; none justifies routine use. Acupuncture in the affected arm appears safe.
Hyperbaric oxygen
- Uncontrolled studies report less breast oedema and pain after radiotherapy; one case of breast oedema resolved (symptoms only, no oedema measure; JBI 5/8). Meier 2023 · Carl 1998
- TcPO2 is normal in lymphoedematous arms, so oedema alone does not create the hypoxia that HBOT targets. Mayrovitz 2005
Laser, heat and physical devices
- Laser: immediate softening and tissue-water fall at fibrotic sites, larger than sham (non-randomised); ISL — limited evidence, more for pain and tissue mobility than volume. A review of laser and endermology reports small volume gains (very low); an overview finds benefit only against weak comparators (low); a 12-patient evaluation is uncontrolled. Mayrovitz 2011 · Wahid 2024 · Wang 2022 · Wigg 2009
- Heat and cold: controlled local heat may reduce swelling and seems safe (very low); heat reduces girth without speeding lymph flow; diathermy does not raise lymph flow; cryotherapy added to physical therapy (small RCT, unclear randomisation). Hill 2024 · Liu 1993 · van der Veen P 2000 · Askary 2022
- Far-infrared thermotherapy (Shanghai): 42 °C for 2 hours daily, 20 sessions, repeated yearly; reported to reduce volume, skin fibrosis and attacks of dermatolymphangioadenitis (78% attack-free for a year, 64-patient retrospective series) — very low. Older therapist texts still list all heat as contraindicated. Liu 2021 · Zuther 2013
- Electrotherapy and ultrasound: ultrasound and faradic current (very low); therapeutic ultrasound no better than pumps; Bodyflow electrical stimulation equalled sham (−302 v −274 mL) though the authors concluded it worked. Hemmati 2022 · Balzarini 1993 · Piller 2010
- Shock wave: reviews and pilots remain preliminary — very low. Zhou 2025 · Miccinilli 2020
- Devices: LPG Endermologie roughly equalled MLD (LPG-funded, unbalanced groups); non-pneumatic compression devices — all evidence manufacturer-funded and unblinded (very low; see compression); IPC in diabetic leg lymphoedema (unregistered pilot; text and figure disagree) — very low. Moseley 2007 · Rockson 2022 · Barfield 2025 · de Sire A 2021
- Negative pressure: incisional NPWT after node dissection (era-confounded, very low); a negative-pressure massage device v MLD after knee replacement (manufacturer-funded). Full NPWT appraisals are in the NPWT library. Poirier 2022 · Weber 2025
Taping
- No volume reduction in reviews (low) and no better than standard care; inferior to CDT at 4 weeks in stage II BCRL; similar to a sleeve in stage I in a small trial; against bandaging with IPC it reduced volume less (0.9% v 2.2%) but was more comfortable — low. Marotta 2023 · González Blanco E 2020 · Basoglu 2021 · Ozsoy-Unubol 2019 · Pajero Otero V 2022
Drugs, supplements and cell therapy
- Reviews: no systemic drug or herbal agent prevents or treats BCRL; nothing supported across 8 RCTs of drugs and cells; the herbs review is uncritical. Review the patient's oedema-causing drugs. Lommer 2026 · Walker 2022 · Sheikhi-Mobarakeh 2020 · Keeley 2008
- Trials: a diosmin–bromelain–melilotus supplement did not reduce leg swelling after pelvic lymphadenectomy (low); synbiotics added nothing (moderate); IV selenium has only a 29-patient metabolomics analysis (very low). Montanaro 2026 · Vafa 2020 · Lee 2021
- Manufacturer-run venoactive trials: Ginkor Fort improved heaviness only; Cyclo 3 Fort beat placebo in one small RCT; coumarin doses were compared without placebo. Coumarin beat placebo in a Shanghai RCT but not in the larger NEJM trial. Cluzan 2004 · Cluzan 1996 · Burgos 1999 · Chang 1996
- Stem-cell (ADRC) lipotransfer: no benefit over placebo. Andersen 2024
- Carboxytherapy: a physiological rationale plus 15 uncontrolled patients given compression at the same time; the review states CO2 contains hydrogen. Does not support use (revised 2026-10-09). Varlaro 2007
Acupuncture and traditional therapies
- Safety: one grade 2 skin infection in 2 965 treatments (225 in the affected arm). Kim 2023
- Effect: low-quality Chinese trials (very low); one meta-analysis reports impossible pooled numbers — disregard it; uniform large effects for meridian sinew tuina in unblinded trials (very low); acupuncture pilot, tuina with moxibustion, neural mobilisation and silicon-oxide point tablets — very low, none affects practice. Yang 2024 · Xu 2024 · Gao 2021 · Zhao 2026 · Friedman 2023 · Wang 2023 · Joshi 2023 · Giron 2025
- Stellate ganglion block after LVA: no between-group effect (pilot RCT; abstract spin). Kang 2026
Gaps and warnings
- Abstracts of several adjunct trials (electrical stimulation, stellate ganglion block, tuina) claim benefit that their own results do not show.
- Device and drug trials are often run or funded by the manufacturer (LPG, Bodyflow, Koya, and the venoactive drug trials).
For the therapist
- Do: offer adjuncts only alongside compression, and only if the patient values a comfort or symptom effect.
- Stop: charging for laser, taping, electrotherapy or devices as volume treatments (no clinically important benefit shown); avoid heat only if it clearly worsens a patient's swelling.
- Certainty: laser and taping low; most others very low.
For a vascular surgeon in South Africa
- HBOT, laser and devices are not a substitute for compression and should not be motivated to medical aids for lymphoedema volume.
- Review drugs that can worsen oedema before adding anything. Keeley 2008
How the evidence points
| High | Mod. | Low | V. low | None | |
|---|---|---|---|---|---|
| Positive | 0 | 0 | 4 | 14 | 0 |
| Null or negative | 0 | 1 | 9 | 5 | 1 |
Sources on this page with a comparison, by the result of their primary outcome and the GRADE certainty of their main finding (Mod. = Moderate, V. low = Very low, None = not graded). Context sources are not counted. How direction is decided.
All 97 sources
Loading 97 sources…